Barclays PLC Krystal Biotech, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Barclays PLC holds 56,540 shares of KRYS stock, worth $9.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

56,540

Previous 56,540 -0.0%

Holding current value

$9.09 Million

Previous $10.3 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$174.7 - $213.66 $6.54 Million - $8 Million	37,452 Added 196.21%	56,540 $10.3 Million
Q2 2024 Aug 14, 2024	SELL	$153.12 - $183.64 $386,781 - $463,874	-2,526 Reduced 11.69%	19,088 $3.51 Million
Q1 2024 May 15, 2024	SELL	$108.01 - $179.35 $4.6 Million - $7.63 Million	-42,565 Reduced 66.32%	21,614 $3.85 Million
Q4 2023 Feb 15, 2024	BUY	$96.0 - $128.29 $2.37 Million - $3.16 Million	24,659 Added 62.4%	64,179 $7.96 Million
Q3 2023 Nov 07, 2023	SELL	$108.51 - $130.22 $771,180 - $925,473	-7,107 Reduced 15.24%	39,520 $4.58 Million
Q2 2023 Aug 03, 2023	BUY	$78.48 - $130.32 $1.31 Million - $2.18 Million	16,734 Added 55.98%	46,627 $5.47 Million
Q1 2023 May 04, 2023	SELL	$72.39 - $84.27 $467,277 - $543,962	-6,455 Reduced 17.76%	29,893 $2.39 Million
Q4 2022 Feb 13, 2023	BUY	$63.14 - $79.9 $203,121 - $257,038	3,217 Added 9.71%	36,348 $2.88 Million
Q3 2022 Nov 03, 2022	BUY	$64.85 - $82.4 $2.07 Million - $2.63 Million	31,925 Added 2647.18%	33,131 $2.31 Million
Q2 2022 Aug 12, 2022	SELL	$48.93 - $73.47 $107,107 - $160,825	-2,189 Reduced 64.48%	1,206 $79,000
Q1 2022 May 16, 2022	SELL	$51.99 - $72.11 $1.17 Million - $1.62 Million	-22,466 Reduced 86.87%	3,395 $225,000
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $523,939 - $1.16 Million	13,161 Added 103.63%	25,861 $1.81 Million
Q3 2021 Nov 09, 2021	BUY	$52.01 - $71.77 $485,461 - $669,901	9,334 Added 277.3%	12,700 $663,000
Q2 2021 Aug 13, 2021	SELL	$62.14 - $81.82 $1.16 Million - $1.53 Million	-18,655 Reduced 84.71%	3,366 $228,000
Q1 2021 May 13, 2021	SELL	$59.42 - $85.46 $173,149 - $249,030	-2,914 Reduced 11.69%	22,021 $1.7 Million
Q4 2020 Feb 11, 2021	SELL	$40.64 - $61.38 $71,485 - $107,967	-1,759 Reduced 6.59%	24,935 $1.5 Million
Q3 2020 Nov 12, 2020	BUY	$37.76 - $48.49 $751,046 - $964,466	19,890 Added 292.33%	26,694 $1.15 Million
Q2 2020 Aug 12, 2020	SELL	$37.03 - $60.0 $93,167 - $150,960	-2,516 Reduced 27.0%	6,804 $282,000
Q1 2020 May 13, 2020	SELL	$35.02 - $65.64 $52,074 - $97,606	-1,487 Reduced 13.76%	9,320 $402,000
Q4 2019 Feb 10, 2020	BUY	$33.17 - $65.23 $10,912 - $21,460	329 Added 3.14%	10,807 $598,000
Q3 2019 Nov 14, 2019	SELL	$34.72 - $51.3 $15,971 - $23,598	-460 Reduced 4.21%	10,478 $364,000
Q2 2019 Aug 14, 2019	SELL	$27.2 - $41.2 $681,305 - $1.03 Million	-25,048 Reduced 69.6%	10,938 $440,000
Q1 2019 May 15, 2019	SELL	$19.86 - $32.9 $27,863 - $46,158	-1,403 Reduced 3.75%	35,986 $1.18 Million
Q4 2018 Feb 14, 2019	BUY	$15.03 - $25.38 $561,956 - $948,932	37,389 New	37,389 $777,000

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.3M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.13B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account